An unusual alliance opens a gene and cell therapy hub outside Boston
Bio Pharma Dive
OCTOBER 27, 2022
Landmark Bio, armed with $75 million and a wide range of backers, is the latest company to emerge with plans to open a “bottleneck” slowing development of the complex medicines.
Let's personalize your content